Intravesical therapy is usually an option for people with noninvasive (stage 0) or minimally invasive (stage I) bladder cancer. With intravesical therapy for bladder cancer, drugs are put directly into the bladder through a catheter, instead of being injected into a vein or swallowed. Both immunotherapy and chemotherapy drugs can be given this way.The most commonly used agents are BCG (Bacillus Calmette-Guérin) and Mitomycin C. It is theorised that BCG stimulates an inflammatory response that promotes malignant cell kill by immunocompetent cells. Mitomycin C, on the other hand, inhibits the synthesis of DNA.
Related Journals of Intravesical Immunotherapy
Immunological Disorders and Immunotherapy, Immunome Research, Journal of Clinical and Cellular Immunology, Immunogenetics: Open Access, Journal of immunotherapy, Journal of Immunological Methods, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy, Cancer Immunology, Immunotherapy
